Indian Prime Minister Narendra Modi on Wednesday approved a plan to set up 20 All India Institutes of Medical Sciences (AIIMS) across the country.
The American Heart Association, one of the leading non-profit organizations that foster cardiac care, is working to enhance community health through a new business line - Health Screening Services (HSS). The new health screening services will help consumers become more conscious of personal health risk factors and motivate them to make changes in their behaviors and lifestyle.
In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
It’s quite frustrating when spending lots of time with a client to have them only inquire about the price of a product and place no orders. So how do we handle this and what steps do we take to improve our business skills and sales rate?
The University Of Kansas Medical Center is partnering with Garmin Health to foster innovation and better understand on how healthcare wearables can help in the detection and management of significant medical conditions. Their first research will focus on cardiac care and sleep apnea.
California-based Casetabs, the pioneer of cloud-based surgery coordination technology, yesterday announced it has received $6 million in series A-funding to scale its surgery coordination application.
CPhI North America was held in Philadelphia, USA from April 24th to April 26th, 2018. Ddu, the leading global pharmaceutical & medical device B2B online platform, attended the exhibition and showcased their new marking model in the United State, but received great feedback from across the globe.
US patient-centric data analytics company, Trayt Technologies (formerly Ava Health), has developed an app to help improve the diagnosis, treatment, and quality of life for patients with autism, ADHD and other neurodevelopmental and brain disorders.
Based on data from the phase II JULIET study, tisagenlecleucel (Kymriah) has received FDA approval for the treatment of adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
T-Stealth™ Oncolytic Virus Platform Expected to Further Strengthen Immunotherapy Platform and Capabilities
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.